Division of Pediatric Cardiology, New York-Presbyterian Morgan Stanley Children's Hospital, Columbia University Irving Medical Center, New York, New York, USA.
Division of Pediatric Cardiac Surgery, New York-Presbyterian Morgan Stanley Children's Hospital, Columbia University Irving Medical Center, New York, New York, USA.
Pediatr Transplant. 2022 May;26(3):e14201. doi: 10.1111/petr.14201. Epub 2021 Dec 10.
Surgical repair for patients with congenital heart disease (CHD) often incorporates homograft tissue or other foreign material that can lead to allosensitization. We sought to identify the relationship between pre-sensitization prior to heart transplant and exposure to homograft tissue in CHD patients.
Retrospective chart review of all CHD patients who underwent heart transplant at a major pediatric transplant center between 1/1/2011-3/31/18. Operative records determined use of homograft tissue or foreign material. Panel reactive antibody (PRA) and Luminex single-antigen bead (SAB) testing results were reviewed. Statistical analysis determined odds of pre-sensitization in patients exposed to homograft tissue.
Fifty-six CHD patients underwent transplant during the review period. Thirteen patients (23%) were pre-sensitized by PRA>10%. By SAB testing, 33 patients (59%) developed any anti-HLA antibody >0 MFI, 30 patients (54%) >2000 MFI, and 19 patients (34%) >6000 MFI. Patients with homografts were more likely to be pre-sensitized by PRA (OR = 7.31, p = .007), and to have developed any anti-HLA antibody at various levels, >0 (OR = 4.52, p = .034), >2000 (OR = 8.59, p = .003), and >6000 (OR = 8.50, p = .004). Of patients with homografts, those pre-sensitized by PRA had longer exposure times (9.80 vs 4.96 years, p = .025). There was no difference in exposure time with relation to pre-sensitization by SAB testing.
Previous exposure to homograft tissue appears to increase the odds of pre-sensitization by either the PRA or SAB testing. Longer exposure time to homograft tissue prior to transplant is associated with increased pre-sensitization at transplant as determined by PRA, though not by SAB testing.
先天性心脏病(CHD)患者的外科修复通常采用同种异体组织或其他异物,这可能导致同种异体致敏。我们试图确定心脏移植前预致敏与 CHD 患者同种异体组织暴露之间的关系。
对 2011 年 1 月 1 日至 2018 年 3 月 31 日在一家主要儿科移植中心接受心脏移植的所有 CHD 患者进行回顾性图表审查。手术记录确定了同种异体组织或异物的使用。回顾了群体反应性抗体(PRA)和 Luminex 单抗原珠(SAB)检测结果。统计分析确定了暴露于同种异体组织的患者预致敏的可能性。
在审查期间,56 例 CHD 患者接受了移植。13 名患者(23%)的 PRA>10%。通过 SAB 检测,33 名患者(59%)产生了任何抗 HLA 抗体>0 MFI,30 名患者(54%)>2000 MFI,19 名患者(34%)>6000 MFI。同种异体组织的患者更有可能通过 PRA 预致敏(OR=7.31,p=0.007),并且在不同水平上产生任何抗 HLA 抗体,>0(OR=4.52,p=0.034),>2000(OR=8.59,p=0.003),>6000(OR=8.50,p=0.004)。同种异体组织的患者中,PRA 预致敏的患者暴露时间更长(9.80 年 vs. 4.96 年,p=0.025)。SAB 检测预致敏与暴露时间无差异。
先前接触同种异体组织似乎增加了通过 PRA 或 SAB 检测预致敏的可能性。与 SAB 检测相比,移植前同种异体组织暴露时间较长与移植前 PRA 检测的预致敏增加相关,但与 SAB 检测无关。